ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag vaccine policy culture genomics

2022 Top 10 Innovations 
2022 Top 10 Innovations
The Scientist | Dec 12, 2022 | 10+ min read
This year’s crop of winning products features many with a clinical focus and others that represent significant advances in sequencing, single-cell analysis, and more.
Opinion: The Politics of Science and Racism
Sadye Paez and Erich D. Jarvis | Aug 18, 2020 | 7 min read
Race has been used to segment humanity and, by extension, establish and enforce a hierarchy in science. Individual and institutional commitments to racial justice in the sciences must involve political activity.
vials in a test kit
Test for Novel Coronavirus Approved for Wide Deployment
Shawna Williams | Feb 6, 2020 | 2 min read
The US Food and Drug Administration authorizes the distribution of the 2019-nCoV diagnostic to state health departments and other facilities.
Updated July 9
Track COVID-19 Vaccines Advancing Through Clinical Trials
The Scientist | Apr 7, 2020 | 10+ min read
Find the latest updates in this one-stop resource, including efficacy data and side effects of approved shots, as well as progress on new candidates entering human studies.
The Year in Pathogens
Molly Sharlach | Dec 28, 2014 | 4 min read
Ebola, MERS, and enterovirus D68; polio eradication efforts; new regulations on potentially dangerous research
Genome Investigator Craig Venter Reflects On Turbulent Past And Future Ambitions
Karen Young Kreeger | Jul 23, 1995 | 8 min read
And Future Ambitions Editor's Note: For the past four years, former National Institutes of Health researcher J. Craig Venter has been a major figure in the turbulent debates and scientific discoveries surrounding the study of genes and genomes. Events heated up in 1991, when NIH attempted to patent gene fragments, which were isolated using Venter's expressed sequence tag (EST)/complementary DNA (cDNA) approach for discovering human genes (M.A. Adams et al., Science, 252:1651-6, 1991). NIH's mo
Special report
501Y.V2 b.1.1.7 B.1.351 coronavirus COVID-19 e484k epidemiology genetics & genomics k417n micro n501y news feature p.1 pandemic SARS-CoV-2 virology variants
A Guide to Emerging SARS-CoV-2 Variants
Katarina Zimmer | Jan 26, 2021 | 10 min read
Scientists across the world are closely tracking the spread of mutations in the coronavirus and investigating whether they could render current vaccines less effective.
How Orphan Drugs Became a Highly Profitable Industry
Diana Kwon | May 1, 2018 | 10+ min read
Government incentives, advances in technology, and an army of patient advocates have spun a successful market—but abuses of the system and exorbitant prices could cause a backlash.
Vaccines: Victims of Their Own Success?
Ricki Lewis | Jul 18, 2004 | 10+ min read
Perhaps in no area is the divide between the developed and developing worlds as striking as it is for vaccines: While healthcare consumers in economically advantaged nations worry about risk, in developing nations compelling need forces a focus on potential benefit. "People in the United States want a quick solution, not prevention, so they prefer drugs to vaccines. Elsewhere, people are afraid of drugs and side effects, and prefer vaccines," says Shan Lu, a primary-care physician who has worked
Best Places to Work Industry, 2012
The Scientist | Jun 1, 2012 | 10+ min read
Much has changed in the 10 years since our first survey of industry researchers. Large companies are now looking to small, nimble ones for services as well as innovation.

Run a Search

ADVERTISEMENT